首页> 外文期刊>European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology >Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: A review
【24h】

Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: A review

机译:铜绿假单胞菌感染在囊性纤维化肺病中的作用及新的治疗方法

获取原文
获取原文并翻译 | 示例
       

摘要

Cystic fibrosis (CF) is a complex inherited disease which affects many organs, including the pancreas and liver, gastrointestinal tract and reproductive system, sweat glands and, particularly, the respiratory system. Pseudomonas aeruginosa is the main cause of chronic airway infection. In order to reduce morbidity and mortality due to lung infection by P. aeruginosa, aerosol antibiotics have been used to achieve high local concentrations in the airways and to reduce systemic toxicity. In the course of this review, the current treatments to control CF lung infections by P. aeruginosa are presented. Some innovative aerosol formulations such as liposomes and microspheres are herein reviewed, which may improve the efficiency of anti-pseudomonal agents, and ensure patients' compliance to treatments, by reducing dosing frequency and/or drug dose, while maintaining therapeutic efficacy, preventing the occurrence of bacterial resistance and/or reducing adverse effects due to their controlled-release properties.
机译:囊性纤维化(CF)是一种复杂的遗传性疾病,会影响许多器官,包括胰腺和肝脏,胃肠道和生殖系统,汗腺,尤其是呼吸系统。铜绿假单胞菌是慢性气道感染的主要原因。为了降低由于铜绿假单胞菌(P.eruginosa)的肺部感染而导致的发病率和死亡率,已经使用气溶胶抗生素来实现气道中的高局部浓度并降低全身毒性。在此审查过程中,介绍了控制铜绿假单胞菌感染CF肺的当前治疗方法。本文对一些创新的气雾剂制剂(如脂质体和微球)进行了综述,它们可通过降低给药频率和/或药物剂量,同时维持治疗功效,防止发生,从而提高抗假单胞菌药物的效率,并确保患者对治疗的依从性由于其控释特性,具有抗细菌性和/或减少不良作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号